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Renal function-based carboplatin dosing is used routinely in paediatric oncology clinical practice. It is important that accurate
assessments of renal function are carried out consistently across clinical centres, a view supported by recently published British
Nuclear Medicine Society (BNMS) guidelines for measuring glomerular filtration rate (GFR). These guidelines recommend the use of
a radioisotope method for GFR determination, with between two and five blood samples taken starting 2h after radioisotope
injection and application of the Brochner-Mortensen (BM) correction factor. To study the likely impact of these guidelines, we have
investigated current practices of measuring GFR in all 21 Children’s Cancer and Leukaemia Group (CCLG) paediatric oncology
centres in the United Kingdom. This information was used to evaluate the potential impact on renal function-based carboplatin dosing
using raw
51Cr-EDTA clearance data from 337 GFR tests carried out in children with cancer. A questionnaire survey revealed that
between two and four samples were taken after isotope administration, with BM and Chantler corrections used in 38% (8/21) and
28% (6/21) of centres, respectively. A change from Chantler to BM correction, based on the BNMS guidelines, would result in a
410% decrease in carboplatin dose in at least 15% of patients and a 425% decrease in 2% of patients. A greater proportion of
patients would have an alteration in carboplatin dose when centres not using any correction factor implement the BM correction. The
increase in estimated
51Cr-EDTA half-life observed by omitting the 1h sample decreases carboplatin dose by 410% in 23–52% of
patients and by 425% in 3% of patients. This study highlights current variations in renal function measurement between clinical
centres and the potential impact on carboplatin dosing. A standard methodology for estimating GFR should be followed to achieve
uniform dosing in children with cancer.
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Carboplatin dosing based on renal function has been shown to
result in more reproducible and reliable drug exposures than
dosing based on surface area in children (Thomas et al, 2000). This
approach not only minimises the risk of underdosing and hence
inadequate treatment, but also reduces overdosing, which may be
associated with the risk of increased toxicity. As renal function-
based carboplatin dosing is now used routinely in clinical practice
in many multicentre protocols, it is important that accurate
assessments of renal function in children are carried out
consistently across paediatric oncology clinical centres.
Glomerular filtration rate (GFR) estimation is widely used as a
standard measure of renal function in both children and adults.
There are many techniques described in the literature to estimate
GFR, using clearance of either exogenous or endogenous markers
(Schwartz et al, 1976; Price and Finney, 2000; Wright et al, 2001;
Leger et al, 2002; Cole et al, 2004; Brandt et al, 2006). Use of
exogenous markers for estimating GFR involves administration of
the marker as either a bolus injection or an infusion and
measurement of concentrations in serial blood and/or urine
samples over a period of time. Radioisotopically labelled inert
substances have been in widespread use and the most common
tracers that have been used are iothalmate (
131I) (Sigman et al,
1966), iodothalmate, chromium ethylenediamine tetracetic acid
(
51Cr-EDTA) and technetium diethylenetriamine pentacetic acid
(
99Tc-DTPA) (Chantler and Barratt, 1972; Hilson et al, 1976; Price
and Finney, 2000). The radioisotope tracers
51Cr-EDTA and
99Tc-
DTPA have found widespread use in paediatric oncology and they
are now accepted as a simple, safe and accurate way of measuring
GFR. In the United Kingdom, it is standard practice in the majority
of Children’s Cancer and Leukaemia Group (CCLG) centres to
estimate GFR using
51Cr-EDTA, whereas in the United States,
99Tc-
DTPA is the radioisotope tracer of choice (Fleming et al, 2004).
Estimation of GFR from the clearance of radiolabelled tracer is
most accurate if multiple blood samples are taken after adminis-
tration as the decrease in plasma concentration of the tracer is
often biexponential, with a rapid early phase and a later slower
phase (Piciotto et al, 1992). However, for routine clinical practice,
sampling is usually restricted to the second phase of the clearance,
with the slope–intercept method commonly used for the
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sdetermination of GFR. As the more rapid early phase of the
clearance is not accounted for when using this method, it is
necessary to correct for systematic errors introduced into the
derived GFR values. The most popular methods used to correct for
these errors are known as the Chantler and Brochner-Mortensen
(BM) corrections (Brochner-Mortensen, 1972; Chantler and Barratt,
1972). Whereas the former uses a constant multiplicative correction
factor to adjust the GFR values obtained, the latter uses a quadratic
correction and is dependent on the individual’s body surface area.
In 2004, the British Nuclear Medicine Society (BNMS) published
guidelines to assist nuclear medicine specialists in performing GFR
studies and interpreting and reporting the results obtained
(Fleming et al, 2004). These guidelines recommended that all
centres should take between 2 and 5 samples, starting 2h after
injection of radioisotope, and that the GFR should be calculated
using the slope–intercept method with the BM correction factor
applied.
As carboplatin dosing represents the main practical outcome of
estimating GFR in paediatric oncology, it would seem sensible to
consider the potential effect that a change in methodology for
estimating GFR may have on carboplatin dosing in children with
cancer. Therefore, to study the likely impact of the BNMS
recommendations, a questionnaire survey concerning the current
practices of estimating GFR in children was sent to all CCLG
paediatric oncology centres in the United Kingdom. This
information was then used to evaluate the potential impact of
these changes on renal function-based carboplatin dosing, using
51Cr-EDTA clearance data from over 300 GFR tests carried out in a
paediatric patient population.
PATIENTS AND METHODS
Questionnaire survey
A survey was conducted by means of a questionnaire circulated to
all 21 CCLG paediatric oncology centres in the United Kingdom.
The questionnaire was sent to centres in May 2006 and all replies
were returned by October 2006. The questionnaire was completed
by a paediatric oncology consultant or paediatric oncology
research nurse in conjunction with the local medical physicist at
each centre. The survey requested detailed information regarding
the methodology currently practiced in estimating GFR in
paediatric oncology patients. The questionnaire also collected
details on the existing practice of estimating carboplatin dose
based on patient renal function in children with cancer. A follow-
up survey was carried out in February 2008 to establish whether
any changes had been made to centre practices since the
completion of the original questionnaire.
Impact of BNMS recommendations on carboplatin dosing
Retrospective data from 337 GFR tests carried out on a total of 178
children in Newcastle upon Tyne were used to study the impact of
the new BNMS recommendations on carboplatin dosing. These
patients had a median weight of 36.6kg (range: 5.0–120.6kg) and a
median age of 12.4 years (range: 0.2–27.4 years). The raw data
used for this analysis were from tests conducted in children
with blood samples taken at 1, 2, 3 and 4h after injection of
51Cr-EDTA and covered a wide range of GFR values. A median
GFR value of 64.7mlmin
 1 (range: 9.7–202.1mlmin
 1), or
95.9mlmin
 11.73m
 2 (range: 14.7–171.2mlmin
 11.73m
 2),
was determined in this patient population, based on the data
obtained from blood samples taken at 2, 3 and 4h and application
of the BM correction. This involved fitting the data from the 2, 3
and 4h samples to a single exponential equation by taking the
natural logarithm of the plasma concentrations and use of linear
regression analysis against time to determine the slope and
intercept at time zero for the exponential. GFR(SI), the clearance
obtained from these data (( 1 dose slope)/intercept), was then
modified, according to the BM equation developed for use in
children (Brochner-Mortensen et al, 1974), to account for the more
rapid early phase of the clearance. To obtain the BM modified
estimate of clearance GFR(BM), the following three steps were
followed:
(1) the BSA corrected, slope–intercept estimate of GFR is given by:
GFRðSIcorrÞ ¼ GFRðSIÞ ð1:73=BSAm2Þ
(2) the BSA corrected and BM-modified estimate of GFR is given
by:
GFRðBMcorrÞ ¼ 1:0004 GFRðSIcorrÞ   0:00146 GFR2
ðSIcorrÞ
(3) the BM modified estimate of GFR is given by:
GFRðBMÞ ¼ GFRðBMcorrÞ ðBSAm2=1:73Þ
This data set from 337 GFR tests was used to estimate the
difference in carboplatin dose that would be seen after imple-
mentation of the new regulations in individual centres. Separate
analyses were performed to assess the impact of omitting the 1-h
blood sample and the implementation of the BM correction in
centres where this was not current practice, i.e., in centres either
applying the Chantler correction or using no correction factor. The
Newell formula based on patient weight and
51Cr-EDTA t1/2,
equation 1, was used to estimate the carboplatin dose to assess the
impact of changing sampling times. This involved the determina-
tion of
51Cr-EDTA t1/2 using the equation: t1/2¼0.693/elimination
rate constant, i.e., using the slope determined from linear
regression of the exponential as described above. The alternative
Newell formula based on uncorrected GFR and patient weight
(modified Calvert formula), equation 2, was used to estimate the
carboplatin dose when centres implemented a change in the
correction factor used (Newell et al, 1993). Both of these formulae
were developed for use in a paediatric patient population and the
comparisons selected, i.e., the effect of blood sampling on use of
the Newell formula and effect of correction factor on use of the
modified Calvert formula, were based on the most practical
combinations with likely clinical relevance.
Dose½mg ¼ AUC½mg=mL:min 
0:693
t1=2½min 
 
:
ð0:52 843 BW½Kg 
0:891Þþð 0:36 BW½Kg Þ

ð1Þ
Dose½mg ¼ AUC½mg=mL:min 
fGFR½mL=min þð 0:36 BW½Kg Þg
ð2Þ
For the purpose of this analysis, a change in carboplatin dose of
more than 10% was considered to be of potential clinical relevance.
RESULTS
Measurement of GFR
A summary of the findings from the questionnaire relating to
current practices in determining renal function in children with
cancer at the UK centres is provided in Table 1. The findings
indicated that at the time the survey was carried out all centres
followed the BNMS guidelines with respect to the use of a
radioisotopic method to measure GFR, with 19 of 21 centres using
51Cr-EDTA and the remaining two centres using
99mTc-DTPA.
Either the central or peripheral route was used to inject the
radioisotope tracer in two-thirds of centres, depending on whether
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sthe patient had a single or a double-lumen central venous line,
whereas the remaining third used the peripheral route only. The
BNMS recommendations indicate the use of one lumen of a
double-lumen central venous line to inject the radioisotope and the
second for blood sampling wherever possible. In situations where
only a single-lumen central venous line is present, the peripheral
route should be used to inject the radioisotope tracer and the
blood samples taken from the central line.
The number and timing of blood samples taken after injection of
radioisotopic tracer varied markedly between centres, with six
centres taking two blood samples, 10 centres taking three samples
and five centres collecting four blood samples. An early blood
sample was taken within 2h of radioisotope administration in 28%
(6/21) of centres, potentially falling within the initial rapid
exponential phase of disappearance of the radioisotope. In-
appropriate inclusion of this early sample in renal function
estimation could potentially lead to the inaccurate determination
of a reduced
51Cr-EDTA t1/2, an increased GFR and resultant
overdosing of carboplatin.
To obtain GFR estimates from the
51Cr-EDTA raw data, all but
one centre (20/21) applied the slope–intercept method, whereas
the remaining centre used an undefined ‘in-house’ method to
determine renal function. Among those centres who applied the
slope–intercept method, 40% (8/20) used the BM correction,
whereas 30% (6/20) applied the Chantler correction. The remain-
ing six centres (30%) applied no correction factor. In the majority
of centres (16/21), the Medical Physics department was responsible
for estimating GFR from the
51Cr-EDTA data obtained, whereas
this task was carried out by the Biochemistry department in the
remaining five centres.
Renal function-based carboplatin dosing
All CCLG centres involved in the treatment of children with cancer
in the United Kingdom routinely use renal function-based
carboplatin dosing as part of chemotherapy regimens for many
different tumour types. Estimation of carboplatin dose was
carried out solely using
51Cr-EDTA t1/2 values in 52% (11/21) of
centres, whereas an additional six centres (29%) used either
51Cr-EDTA t1/2 or uncorrected GFR obtained from the EDTA data.
The remaining 10% (2/21) of centres exclusively used uncorrected
GFR as the renal parameter, in conjunction with patient body
weight, to estimate the carboplatin dose to be administered.
Glomerular filtration rate measurement and carboplatin
dosing
Implementation of the BNMS guidelines, i.e., using data obtained
from blood samples taken at 2, 3 and 4h and application of the BM
correction, resulted in a median EDTA t1/2 value of 93.5min
(range: 47.4–481.8min) and a median carboplatin dose (calculated
to achieve an AUC of 5.0mgml
 1min
 1) of 416mg (range: 72–
1207mg) in this patient population. On the basis of the above
findings from the questionnaire survey, implementation of these
guidelines would result in the omission of data obtained from early
blood samples taken within 2h of radioisotope administration in
six centres. In addition, 12 centres would shift from either applying
no correction, or using the Chantler correction, to implement
the BM correction. The consequences of these changes on
renal function-based carboplatin dosing are summarised in
Tables 2 and 3.
These data show the percentage of children who would have
a 410% change in carboplatin dose following the implementation
of the BNMS recommendations, including both increases
and decreases to the calculated carboplatin dose. Following
omission of the early blood sample in those centres where this
was taken, the
51Cr-EDTA t1/2 increased in the majority of
patients, with a resultant decrease in dose of carboplatin calculated
on the basis of
51Cr-EDTA t1/2 and weight as expected. A change
in carboplatin dose of 410% would be seen in 23–52% of
patients treated at these centres, depending on the existing
sampling times in place. The vast majority of patients would have
a decrease in the dose of carboplatin administered following the
omission of the early blood sample, as illustrated in Figure 1A. In a
small group of patients (3%), the dose difference could be as high
as 25%.
With regards to the slope–intercept correction method used, a
shift from the Chantler correction to the BM correction would
result in a 410% change in carboplatin dose in at least 15% of
children (Table 3). In a small group of patients (2%), the change in
Table 1 Results of the questionnaire survey showing the methodology of estimation of GFR in the UK CCLG centres
Centre Radioisotope
Route of
injection
No of
samples
Early sampling
(o2h)
GFR
estimation Methodology
Correction
factor
1
51Cr-EDTA Peripheral 3 Yes Med Physics Slope–intercept BM
2
51Cr-EDTA Central 2 No Biochemistry Slope–intercept Chantler
3
51Cr-EDTA Central 2 No Biochemistry Slope–intercept Chantler
4
51Cr-EDTA Central 4 No Med Physics Slope–intercept Chantler
5
51Cr-EDTA Peripheral 4 No Med Physics Slope–intercept BM
6
51Cr-EDTA Both 4 Yes Med Physics Slope–intercept BM
7
51Cr-EDTA Both 3 No Med Physics Slope–intercept BM
8
51Cr-EDTA Both 3 No Med Physics Slope–intercept Modification
9
99mTc-DTPA Both 2 No Med Physics Slope–intercept None
10
51Cr-EDTA Both 3 No Med Physics Slope–intercept Chantler
11
51Cr-EDTA Peripheral 3 No Med Physics Slope–intercept BM
12
51Cr-EDTA Peripheral 2 No Biochemistry Slope–intercept None
13
51Cr-EDTA Both 2 No Biochemistry Slope–intercept Chantler
14
51Cr-EDTA Both 3 Yes Med Physics Slope–intercept None
15
51Cr-EDTA Peripheral 3 No Med Physics Slope–intercept None
16
51Cr-EDTA Both 4 No Med Physics Slope–intercept BM
17
99mTc-DTPA Both 2 No Med Physics Slope–intercept BM
18
51Cr-EDTA Both 3 Yes Med Physics In-house method None
19
51Cr-EDTA Peripheral 3 Yes Biochemistry Slope–intercept None
20
51Cr-EDTA Central 4 Yes Med Physics Slope–intercept Chantler
21
51Cr-EDTA Peripheral 3 No Med Physics Slope–intercept BM
BM¼Brochner-Mortensen; CCLG¼Children’s Cancer and Leukaemia Group; GFR¼glomerular filtration rate.
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sdose could be as high as 25%. In centres applying no correction
factor, introduction of the BM correction would impact on a
greater proportion of patients, with a 410% change in carboplatin
dose observed in 72–85% of children; the change in dose could be
as high as 25% in 6–14% of patients. Although the proportion of
patients who would experience a significant carboplatin dose
change is substantial, the actual mean percentage dose change
would be relatively small, ranging from 14–17% across different
centres.
Introduction of the BM correction (instead of the Chantler or no
correction) would be expected to result in a higher estimate of
AUC and the clearance of
51Cr-EDTA would decrease. Conse-
quently, this would lead to a decrease in the dose of carboplatin
calculated using the Newell formula on the basis of uncorrected
GFR and weight. An example of the distribution of carboplatin
dose adjustment when the Chantler correction is substituted by the
BM correction is illustrated in Figure 1B.
DISCUSSION
There are numerous techniques described in the literature for
estimating renal function or GFR in children and adults (Price and
Finney, 2000; Wright et al, 2001; Leger et al, 2002; Cole et al, 2004;
Brandt et al, 2006). Although creatinine clearance is a reliable
marker in day-to-day practice in adults, its use in paediatrics has
been questioned and there are situations where a more accurate
measure of GFR is preferred (Finney et al, 2000; Holweger et al,
2005). This information may be particularly important in clinical
situations where potentially nephrotoxic drugs are administered,
in addition to allowing for accurate renal function-based dosing of
anticancer drugs such as carboplatin (Calvert et al, 1989; Holweger
et al, 2005). It has been well established that the use of radioisotope
tracers, such as
51Cr-EDTA and
99mTc-DTPA, are reliable methods
for the accurate estimation of GFR (Rehling et al, 1984; Fawdry
et al, 1985). Techniques of limited sampling restricted to the slow
exponential phase of radioisotope clearance provide a reasonable
compromise to avoid the complexity of measuring GFR using the
biexponential method where multiple blood samples need to be
taken at earlier time points. This is particularly important in
paediatric practice where blood sampling can be a traumatic
experience to a child and where blood volumes need to be
minimised. However, this approach necessitates the use of an
appropriate correction factor to offset the overestimation of GFR
by the slope–intercept technique.
An audit carried out by the BNMS previously highlighted the
problems of widespread variation in hospital practices for
measuring GFR and guidelines have been published in an attempt
to standardise the methodologies used. In view of the BNMS
recommendations, it was prudent to investigate the potential
effects of changes in methodologies for determining GFR on
carboplatin dosing in children with cancer. Therefore, this study
aimed to investigate current practices for determining GFR in
paediatric oncology centres across the United Kingdom and to use
the information obtained to investigate the potential impact of the
BNMS recommendations on renal function-based dosing of
carboplatin in patients.
Information obtained from all 21 CCLG centres responsible for
the treatment of children with cancer in the United Kingdom
showed that, to comply with the BNMS recommendations, six
centres would be required to stop taking early blood samples (less
than 2h after radioisotope injection) and 12 centres would need to
implement the use of the BM slope–intercept correction method.
These factors are important when we consider that use of a sample
taken 1h after radioisotope injection, potentially falling within the
rapid early phase of elimination, in combination with the slope–
intercept method, could lead to inaccurate GFR determinations
and potential overdosing of carboplatin. Using raw
51Cr-EDTA
data from 337 GFR tests carried out in children with cancer, in
conjunction with the findings of the questionnaire survey, it was
possible to study the potential impact of the new recommendations
on carboplatin dosing.
Table 3 Predicted impact on renal function-based carboplatin dosing of a change from current practices to the new sampling times and correction factor
recommended by BNMS
Existing sampling
times (h)
Existing correction
factor
New sampling
times (h)
New correction
factor
Number of
centres
Percentage of children with 410%
carboplatin dose change
1, 2, 3 and 4 None 2,3 and 4 BM 1 72
1, 2 and 3 None 2,3 and 4 BM 3 80
2 and 4 None 2,3 and 4 BM 2 85
2, 3 and 4 None 2,3 and 4 BM 1 85
2, 3 and 4 Chantler 2,3 and 4 BM 2 15
2 and 4 Chantler 2,3 and 4 BM 3 15
1, 3 and 4 BM 2,3 and 4 BM 1 4
2 and 3 BM 2,3 and 4 BM 1 4
2, 3 and 4 BM 2,3 and 4 BM 5 No change
Others — 2,3 and 4 BM 2 Not applicable
BM¼Brochner-Mortensen; BNMS¼British Nuclear Medicine Society. Dosing based on uncorrected GFR and weight.
Table 2 Predicted impact on renal function-based carboplatin dosing of a change from existing sampling times to the new BNMS guidelines
Existing sampling
times (h)
New sampling
times (h)
Number of
centres
Percentage of children who have
a 410% change in carboplatin dose
1, 2, 3 and 4 2,3 and 4 1 23 (21% increase/2% decrease)
1, 2 and 3 2,3 and 4 3 52 (47% increase/5% decrease)
2 and 4 2,3 and 4 5 No change
2, 3 and 4 2,3 and 4 8 No change
1, 3 and 4 2,3 and 4 1 27 (25% increase/2% decrease)
2 and 3 2,3 and 4 1 33 (23% increase/10% decrease)
Others — 2 —
BNMS¼British Nuclear Medicine Society. Dosing on the basis of
51Cr-EDTA t1/2 and weight.
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sOn performing the analyses of various possible combinations of
sampling times, it was found that changing from the Chantler to
the BM correction factor altered the dose of carboplatin estimated
by more than 10% in at least 15% of the children studied. In a
small group of patients (2%), the dose difference was as high as
25%. However, the impact was even more marked when changing
from no correction to the BM correction, with a 410% change in
carboplatin dose observed in 72–85% of children. Omitting the
1-h blood sample after injection of the radioisotope increased
the estimate of
51Cr-EDTA half-life and consequently decreased
the dose of carboplatin estimated using
51Cr-EDTA half-life and
weight. The alteration in the estimated dose was 410% in 23–52%
of the children studied and in 3% of patients, the dose would
decrease by 425%.
Whether or not the magnitude of these changes in carboplatin
dosage would impact on the ultimate clinical outcome has not been
prospectively evaluated and the heterogeneity of the cases in our
study population (from whom GFR study data were obtained)
would make such an analysis difficult. Also, the 10% change of
carboplatin dose used for our analysis represents an arbitrary
cutoff point. Although subjective, in view of the narrow
therapeutic windows for chemotherapy agents, most clinicians
would consider a 410% dose change for any chemotherapeutic
drug as being significant. As the predominant shift is towards a
decrease in carboplatin dose, implementation of the BNMS
recommendations should not raise any concerns regarding
potential increases in drug toxicity but an impact on efficacy
cannot be ruled out.
These findings highlight the potential problem that patients with
similar physical characteristics and renal function could receive
different carboplatin doses at different centres on the basis of the
methodology used to estimate GFR or
51Cr-EDTA half-life. Indeed,
it is not unlikely for such an occurrence to be observed in patients
being treated on the same clinical protocol. As many paediatric
oncology patients in the United Kingdom are recruited to national
and international trials, it is logical that the methodology of
estimating GFR and carboplatin dose estimation should be
standardized, so that the outcome data for these trials are not
confounded by this factor. This task could arguably be made more
straightforward if the Newell formula was universally used for the
determination of renal function-based carboplatin dosing in
children, as the
51Cr-EDTA half-life on which it is based is only
dependent on the radioisotope sampling times and does not
depend on the choice of correction factor. Implementation of a
change in the type of slope–intercept correction method used for
determining GFR, in addition to the changes in sampling times,
would impact on the majority of CCLG centres (16 of 21) and there
may be some reluctance to implement such changes. Despite the
publication of the BNMS recommendations in 2004, there remains
substantial variation in practice in paediatric oncology centres
across the United Kindom. Indeed, in a follow-up survey carried
out as part of this study in February 2008, only three centres
reported a change to the previously used method of GFR
determination. While one centre had adopted the BNMS recom-
mendations during this time interval, changes in the additional
two centres related to the inclusion of a third
51Cr-EDTA sampling
time point and a shift from the use of
51Cr-EDTA to iohexol as the
radioisotopic tracer, respectively. There has also been confusion
between the use of ‘uncorrected GFR’, the parameter used in the
modified Calvert formula for estimating carboplatin dose, and
body surface area or weight ‘standardized’ or ‘normalized’ GFR
with reports in the literature where serious dosing errors have
occurred when these values have been misused (Liem et al, 2003).
The standardised use of
51Cr-EDTA half-life as the renal parameter
to estimate carboplatin dose would prevent such problems
occurring.
In summary, our findings suggest that steps should be taken to
implement the new BNMS guidelines and standardise methodo-
logies of GFR estimation and renal function-based carboplatin
dose calculation in all centres. Ideally, we recommend the
determination of carboplatin dose in children with cancer on the
basis of
51Cr-EDTA half-life and weight wherever possible.
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Figure 1 Distribution of percentage change in carboplatin dose
following a change in sampling times from 1, 2, 3 and 4h to 2, 3 and 4h
(A), and following a shift from the Chantler correction to the Brochner-
Mortensen correction with sampling times at 2, 3 and 4h (B). A decrease
in dose is seen for the majority of patients in both cases.
Renal function estimation and carboplatin dosing in children
G Chinnaswamy et al
898
British Journal of Cancer (2008) 99(6), 894–899 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sREFERENCES
Brandt JR, Wong CS, Hanrahan JD, Qualls C, McAfee N, Watkins SL (2006)
Estimating absolute glomerular filtration rate in children. Pediatr
Nephrol 21: 1865–1872
Brochner-Mortensen J (1972) A simple method for the determination of
glomerular filtration rate. Scand J Clin Lab Invest 30: 271–274
Brochner-Mortensen J, Haahr J, Christoffersen J (1974) A simple method
for accurate assessment of the glomerular filtration rate in children.
Scand J Clin Lab Invest 33: 139–143
Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE,
Siddik ZH, Judson IR, Gore ME (1989) Carboplatin dosage: prospective
evaluation of a simple formula based on renal function. J Clin Oncol 7:
1748–1756
Chantler C, Barratt TM (1972) Estimation of glomerular filtration-rate from
plasma clearance of 51-chromium edetic acid. Arch Dis Child 47:
613–617
Cole M, Price L, Parry A, Keir MJ, Pearson ADJ, Boddy AV, Veal GJ (2004)
Estimation of glomerular filtration rate in paediatric cancer patients
using
51CR-EDTA population pharmacokinetics. Br J Cancer 90: 60–64
Fawdry RM, Gruenewald SM, Collins LT, Roberts AJ (1985) Comparative-
assessment of techniques for estimation of glomerular-filtration rate with
Tc-99m-Dtpa. Eur J Nucl Med 11: 7–12
Finney H, Newman DJ, Thakkar H, Fell JME, Price CP (2000) Reference
ranges for plasmacystatin C and creatinine measurements in premature
infants, neonates, and older children. Arch Dis Child 82: 71–75
Fleming JS, Zivanovic MA, Blake GM, Burniston M, Cosgriff PS (2004)
Guidelines for the measurement of glomerular filtration rate using
plasma sampling. Nucl Med Commun 25: 759–769
Hilson AJW, Mistry RD, Maisey MN (1976) Tc-99m – Dtpa for
measurement of glomerular-filtration rate. Br J Radiol 49: 794–796
Holweger K, Bokemeyer C, Lipp HP (2005) Accurate measurement of
individual glomerular filtration rate in cancer patients: an ongoing
challenge. J Cancer Res Clin Oncol 131: 559–567
Leger F, Bouissou F, Coulais Y, Tafani M, Chatelut E (2002) Estimation of
glomerular filtration rate in children. Pediatr Nephrol 17: 903–907
Liem RI, Higman MA, Chen AR, Arceci RJ (2003) Misinterpretation of a
Calvert-derived formula leading to carboplatin overdose in two children.
J Pediatr Hematol Oncol 25: 818–821
Newell DR, Pearson ADJ, Balmanno K, Price L, Wyllie RA, Keir M, Calvert
AH, Lewis IJ, Pinkerton CR, Stevens MC (1993) Carboplatin pharmaco-
kinetics in children – the development of a pediatric dosing formula.
J Clin Oncol 11: 2314–2323
Piciotto G, Cacace G, Cesena P, Mosso R, Ropolo R, De Filippi PG (1992)
Estimation of chromium-51 ethylene diamine tetra-acetic plasma
clearance: a comparative assessment of simplified techniques. Eur J
Nucl Med 19: 30–35
Price CP, Finney H (2000) Developments in the assessment of glomerular
filtration rate. Clinica Chimica Acta 297: 55–66
Rehling M, Moller ML, Thamdrup B, Lund JO, Trap-Jensen J (1984)
Simultaneous measurement of renal clearance and plasma-clearance of
Tc-99m-labelled diethylenetriaminepenta-acetate, Cr-51-labeled ethylene-
diaminetetra-acetate and inulin in man. Clin Sci 66: 613–619
Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A (1976) A simple
estimate of glomerular filtration rate in children derived from body
length and plasma creatinine. Pediatrics 58: 259–263
Sigman E, Elwood C, Knox F (1966) The measurement of glomerular
filtration rate in man with sodium Iothalamate 131-I. J Nuc Med 7: 60–68
Thomas HD, Boddy AV, English MW, Hobson R, Imeson J, Lewis I,
Morland B, Pearson ADJ, Pinkerton R, Price L, Stevens M, Newell DR
(2000) Prospective validation of renal function-based carboplatin dosing
in children with cancer: a United Kingdom children’s cancer study group
trial. J Clin Oncol 18: 3614–3621
Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH (2001)
Estimation of glomerular filtration rate in cancer patients. Br J Cancer 84:
452–459
Renal function estimation and carboplatin dosing in children
G Chinnaswamy et al
899
British Journal of Cancer (2008) 99(6), 894–899 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s